Comparison

Recombinant Monkeypox Virus Cell Surface-binding Protein, E8L

Item no. 230-30232-250
Manufacturer Raybiotech
Amount 250 ug
Quantity options 100 ug 250 ug
Category
Type Proteins Recombinant
Format Lyophilized
Applications WB, IP, ELISA, Dot
Specific against Virus, Monkeypox
Host HEK293 cells
Conjugate/Tag HIS
Purity >95%
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Shipping Condition Room temperature
Available
Manufacturer - Applications
Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.
Manufacturer - Category
Proteins|Recombinant Proteins|Viral Proteins
Manufacturer - Conjugate / Tag
C-terminal his-tag
Shipping Temperature
Ambient temperature
Storage Conditions
-20°C
Molecular Weight
Recombinant protein product has a calculated molecular mass of ∼32 kDa. Due to the abundant glycosylation, it migrates as approximately ∼40 kDa protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. See deglycosylation analysis image below.
Description
Recombinant Monkeypox virus (MPXV) cell surface-binding protein E8L with C-terminal His-tag, derived from the transfected human HEK293 cells.
Purity determined by
SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Gene Symbols
E8L
UNSPSC Code
12352202
Formulation
Lyophilized from a 0.2 µm filtered solution in PBS (pH 7.4) with 1% mannitol and 5% trehalose
Expressed Region
Met1-Thr275
Protein Name & Synonyms
Cell surface-binding protein, carbonic anhydrase homolog, E8L
Format
Lyophilized powder
Purification
His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Reconstitution
Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1 mg/mL with sterile deionized water.
Endotoxin Level
<0.5 EU per ug of the protein as determined by the LAL method
SDS-PAGE Image
Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: protein standard ladder (kDa).Lane 2: untreated protein.Lane 3: treated protein with deglycosylation enzymes under native conditions.Lane 4: treated protein with deglycosylation enzymes under denature conditions.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 250 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close